Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Mylan's Generic EpiPen: A Good PR Move, But Risks Alienating Payers

Executive Summary

Mylan's plan to provide a generic version of its emergency allergic reaction drug EpiPen may be a good PR move, but it may alienate payers further. It also has spurred new skepticism about the company's pricing practices.


Related Content

Express Scripts Pushing Manufacturers To Lower List Prices By Offering Cheaper Brand Alternatives
Investors Relieved As Mylan Settlement Avoids Investigation
How Many Pricing Hearings Add Up To Action On Pricing Transparency?
EpiPen Familiarity May Prove Tough Hurdle For Generics
EpiPen Medicaid Rebates Could Increase As Mylan, CMS Dispute Heats Up
Mylan's EpiPen Nightmare Not Over Yet, But Will Congress Just Write?
EpiPen Price Story Highlights Growing Impact Of Drug Deductibles
Mylan Could Get Out Of EpiPen Price Backlash With A Little Contrition, Analyst Says
EpiPen's Swollen Price May Trigger Patient Assistance Program Probes
Mylan’s EpiPen Exclusivity Saved Again As Teva Reports CRL


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts